Treating Neuroendocrine Prostate Cancer
William K. Oh, MD, explores neuroendocrine prostate cancer, emphasizing its increasing prevalence and aggressive nature.
Read MoreWilliam K. Oh, MD, is the Director of Precision Medicine at the Yale Cancer Center, and a Professor of Medicine for the Division of Medical Oncology at Yale School of Medicine in New Haven, Connecticut. Dr. Oh also serves as Medical Director for the Service Line at Smilow Cancer Hospital within the Greenwich Hospital. Dr. Oh’s specialties include the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers. Dr. Oh’s research interests include novel biomarkers and therapeutics in advanced prostate cancer.
Dr. Oh received his medical degree from New York University School of Medicine in New York, New York. He completed his internship and residency in Internal Medicine at Brigham and Women’s Hospital in Boston, Massachusetts. He then completed a fellowship in Medical Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. Prior to joining Mount Sinai in 2009, Dr. Oh served as Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. He was also the founding Chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center.
In addition to serving as the Principal Investigator of multiple clinical trials in prostate cancer, Dr. Oh has developed large clinical databases and specimen repositories for genitourinary cancers at Harvard Medical School and the Dana-Farber Cancer Institute and at Mount Sinai, which have enrolled more than 10,000 patients with prostate, renal, and bladder cancers. Dr. Oh has authored more than 350 articles, reviews, and book chapters on topics relating to prostate, renal, bladder, and testicular cancers. He has edited three books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association, including the Guidelines Committee for Advanced Prostate Cancer. In addition to reviewing for top journals such as The New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr. Oh co-edits “Testicular Cancer” for Up to Date and is Associate Editor of CA: A Cancer Journal for Clinicians. He is a member of the prestigious American Society for Clinical Investigation and has been repeatedly selected as a Top Doctor in New York magazine, Castle Connolly, Best Doctors, and Super Doctors over the past decade.
William K. Oh, MD | Apr 2025
William K. Oh, MD, explores neuroendocrine prostate cancer, emphasizing its increasing prevalence and aggressive nature.
Read MoreWilliam K. Oh, MD | Feb 2025
William K. Oh, MD, discusses prostate cancer diagnosis and treatment, focusing on PSMA diagnostics and LU-177 PSMA therapy.
Read MoreWilliam K. Oh, MD | Dec 2024
William K. Oh, MD, discusses systemic immunotherapy approaches for advanced prostate cancer.
Read MoreWilliam K. Oh, MD; Alan H. Bryce, MD; Oliver Sartor, MD
Read MoreWilliam K. Oh, MD; Alan H. Bryce, MD; Oliver Sartor, MD; Juanita M. Crook, MD, FRCPC; James A. Eastham, MD, FACS
Read More